Appendix 3B and Appendix 3Y Withdrawn
Melbourne, Australia 25 February 2020 CLINUVEL PHARMACEUTICALS LTD (“Company”) withdraws the Appendix...
Read More
CLINUVEL Expands Singapore Laboratories
CLINUVEL PHARMACEUTICALS LTD today announced that it is investing in the further...
Read More
Request for FDA Guidance Meeting SCENESSE® in Vitiligo
CLINUVEL requests Type C Guidance meeting to progress the clinical program in...
Read More
Australian TGA commences SCENESSE® review
EXECUTIVE SUMMARY SCENESSE® (afamelanotide 16mg) technology review starts in Australia for rare...
Read More
Appendix 4C
CLINUVEL PHARMACEUTICALS LTD, a global biopharmaceutical company focused on developing and delivering...
Read More
CLINUVEL Kommuniqué I
Sehr geehrte Aktionärinnen und Aktionäre, liebe Freunde Im Namen des CLINUVEL-Ausschusses wünsche...
Read More
CLINUVEL Newsletter
Dear shareholders, friends On behalf of the CLINUVEL Board, I wish you...
Read More
SCENESSE® registration dossier submitted in Australia
CLINUVEL initiates the registration process under priority review for its new pharmaceutical...
Read More
Notice of Change of Interests of Substantial Holder
Form 604 – Notice of change of interests of substantial holder...
Read More
Change of Director's Interest Notice
Appendix 3Y – Change of Director’s Interest Notice, is available to download.
Read More
Lapse and Forfeit of Unlisted Conditional Performance Rights
CLINUVEL PHARMACEUTICALS LTD wishes to advise in accordance with the terms and...
Read More
Changes of Director's Interest Notice
Appendix 3Y Change of Director’s Interest Notice Download PDF
Read More
Appendix 3B
New issue announcement, application for quotation of additional securities and agreement. Download...
Read More
Changes in Composition to Committeess
CLINUVEL PHARMACEUTICALS LTD today announced changes to the composition of its Audit...
Read More